Acute nontraumatic weakness has a varied etiology and presentation. Myasthenia gravis and Guillain–Barré Syndrome are the two most widely discussed diseases of this subgroup. However, their management is still riddled with a few obscurities that need validation. The choice between plasmapheresis and intravenous immunoglobin in the management of acute nontraumatic weakness, the decision to continue or withhold acetylcholinesterase inhibitors during myasthenic crisis, the Implications of the second dose of IVIg in neurocritical care, the role of noninvasive ventilation (NIV) in neuromuscular weakness, and the search for ideal weaning strategy in patients requiring ventilatory support are a few gray areas which are bound to be addressed. A comprehensive review of recent literature and recommendations from professional bodies on the above subjects has been made and presented in the following chapter.